Blog
Latest articles, insights, and updates from the blog.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
Esketamine for Treatment-Resistant Depression: How It Works
How esketamine (Spravato) treats treatment-resistant depression: FDA approval history, eligibility, dosing schedule, and the REMS safety program.
Is Ketamine a Controlled Substance? Schedule III Status Explained
Ketamine is a Schedule III controlled substance under U.S. federal law. Learn what that classification means for prescribing, dispensing, and patient access.
Ketamine Dosing Explained: Therapeutic Ranges by Route
See ketamine dosing ranges for depression and pain across IV, intramuscular, intranasal, sublingual, and oral routes, plus how titration and safety checks work.
Boston Clinics Spotlight Ketamine's Growing Role in Mental Health
Boston clinics are expanding ketamine therapy for mental health. What patients should know about access, cost, and what to expect from treatment.
Is Ketamine the Future of Mental Health Treatment?
A local news segment spotlights ketamine therapy's growing role in mental health. Here's what the coverage gets right — and what patients should know.
Psych Deprescribing Debate: What It Means for Ketamine
HHS targets psychiatric overprescribing. Experts say stop what's not working—and replace it with evidence-based alternatives. Here's how ketamine fits in.
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial found that pairing esketamine with 16 weeks of CBT reduced suicidal ideation and depression severity better than esketamine alone.
Schizophrenia Survey Reveals Gaps That Echo Across Psychiatry
A new SPAN survey exposes persistent care gaps in schizophrenia treatment. Here's why those findings matter across the broader psychiatric landscape.
Faster TRD Remission: Why Measurement-Based Care Matters
New clinical guidance on TRD emphasizes fast dose adjustments and symptom tracking—here's what it means for patients considering ketamine therapy.
Ketamine Side Effects: What the Data Says on Dropout
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients and providers set realistic expectations for ketamine treatment.
Faster TRD Remission: What Smarter Dosing Means for You
New guidance on treatment-resistant depression stresses faster dose adjustments and symptom tracking. Here's what it means for ketamine therapy patients.
Ketamine Side Effects: What the Data Now Shows
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives ketamine patients a clearer picture of what to expect and when to switch.